[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-339881-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-339881-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","a-case-of-response-to-combination-treatment-with-tsa-dc-ctl-immunotherapy-and-osimertinib-in-egfr-mutated-advanced-lung-adenocarcinoma","A case of response to combination treatment with TSA-DC-CTL immunotherapy and osimertinib in EGFR mutated advanced lung adenocarcinoma","","Background: The report describes a patient with advanced lung adenocarcinoma carrying an EGFR exon 19 deletion. Method: A 46-year-old woman with stage IVb disease received combination therapy after tumor-specific antigen peptides were identified, using TSA-DC-CTL immunotherapy together with oral osimertinib. Peripheral blood immune cells and circulating tumor cells (CTCs) were measured before and after treatment, while PET-CT and CT imaging evaluated response. Results: Total lymphocytes increased and CTCs decreased, accompanied by reduced metastatic lesions on imaging. Conclusion: The findings support the safety and efficacy of TSA-DC-CTL combined with osimertinib for this EGFR-mutated setting.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/a-case-of-response-to-combination-treatment-with-tsa-dc-ctl-immunotherapy-and-osimertinib-in-egfr-mutated-advanced-lung-adenocarcinoma/339881/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/a-case-of-response-to-combination-treatment-with-tsa-dc-ctl-immunotherapy-and-osimertinib-in-egfr-mutated-advanced-lung-adenocarcinoma/339881.png","ImageObject",300,407,{"name":42,"@type":43},"Asher","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What patient and genetic feature are described in the case report?","Question",{"text":63,"@type":64},"The report involves a patient with advanced lung adenocarcinoma harboring an EGFR exon 19 deletion.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What combination treatment was administered, and how was response monitored?",{"text":68,"@type":64},"The patient received TSA-DC-CTL immunotherapy combined with oral osimertinib. Response was tracked using peripheral blood analyses of immune cells and CTC counts, as well as PET-CT and CT imaging.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the main outcomes after treatment?",{"text":72,"@type":64},"The study observed an increase in total lymphocyte percentage, a decrease in CTC numbers, and a reduction in tumor metastases on imaging.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},339881,1790075442,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},"Research & Report",30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":123,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Han et al. Molecular Cancer (2024) 23:163 [https://doi.org/10.1186/s12943-024-02070-3](https://doi.org/10.1186/s12943-024-02070-3)  \nMolecular Cancer  \nCORRESPONDENCE Open Access  \nA case of response to combination   \ntreatment with TSA-DC-CTL immunotherapy and osimertinib in EGFR mutated advanced lung adenocarcinoma  \nZhiyi Han 1†, Tao Li2†, Heng Zhang3, Kai Liang3, Mingcong You3, Mengdi Xu3, Fan Bai3 and Tongmei Zhang4*  \nAbstract  \nBackground This study details a case of a patient with advanced lung adenocarcinoma harboring an exon 19 deletion in the EGFR gene.  \nMethod A 46-year-old female patient was diagnosed with stage IVb left lung adenocarcinoma, with multiple bone and lymph node metastases. Following the identification of tumor-specific antigen peptides, the patient received a combination treatment of immunotherapy (TSA-DC-CTL) and oral osimertinib. Peripheral blood circulating immune cells and circulating tumor cells (CTCs) were monitored before and after treatment. PET-CT and CT scans were used to assess the tumor response to treatment.  \nResults A significant increase in total lymphocyte percentage and decrease in the number of CTCs in the patient was observed. Imaging studies showed a notable reduction in tumor metastases.  \nConclusion This report demonstrates the safety and efficacy ofTSA-DC-CTL cell immunotherapy combined with osimertinib in the treatment of a patient with advanced lung adenocarcinoma with an EGFR exon 19 deletions. This study describes a promising new treatment option for patients with advanced lung cancer with EGFR mutations. Keywords Cellular immunotherapy, TSA-DC-CTL, EGFR gene mutation, Advanced lung cancer  \n†Zhiyi Han and Tao Li contributed equally to this work.  \n*Correspondence: Tongmei Zhang [tongmeibj@163.com](tongmeibj@163.com)  \n1Department of Surgery, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China  \n2Department of Medical Oncology, Affiliated Tumor Hospital of Nantong University & Nantong Tumor Hospital, Nantong 226361, China 3Healthy Cell Biotechnology LLC, Beijing 100036, China  \n4Department of Medical Oncology, Beijing Chest Hospital, Beijing Tuberculosis and Thoracic & Laboratory for Clinical Medicine, Capital Medical University, Beijing 101149, China  \nIntroduction  \nPrimary lung cancer is the most prevalent malignant tumor in China. Based on the GLOBOCAN 2020 data, China contributes to 37.0% of the global lung cancer incidence and 39.8% of related deaths [1]. From pathological and therapeutic perspectives, lung cancer is categorized into non-small cell lung cancer (NSCLC) and small cell lung cancer, with NSCLC accounting for approximately 80–85% of cases, including histological subtypes such asadenocarcinoma and squamous cell carcinoma. The standard treatment options for patients with NSCLC include radiotherapy and chemotherapy. These approaches typically suppress tumor cell proliferation or induce cell  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://](http://)[ ](http://)[creativecommons.org/l](cr","cbCaiaJBz9viJzyh","https://ap.wps.com/l/cbCaiaJBz9viJzyh","pdf",1823007,"English","# Abstract\n## Background\n## Method\n## Results\n## Conclusion\n# Introduction\n## Lung cancer burden and standard treatments\n## Cellular immunotherapy and dendritic cell function\n## Immune editing and tumor immune escape\n# Correspondence","[{\"question\":\"What patient and genetic feature are described in the case report?\",\"answer\":\"The report involves a patient with advanced lung adenocarcinoma harboring an EGFR exon 19 deletion.\"},{\"question\":\"What combination treatment was administered, and how was response monitored?\",\"answer\":\"The patient received TSA-DC-CTL immunotherapy combined with oral osimertinib. Response was tracked using peripheral blood analyses of immune cells and CTC counts, as well as PET-CT and CT imaging.\"},{\"question\":\"What were the main outcomes after treatment?\",\"answer\":\"The study observed an increase in total lymphocyte percentage, a decrease in CTC numbers, and a reduction in tumor metastases on imaging.\"}]","A case of response to combination treatment with TSA-DC-CTL immunotherapy and osimertinib in EGFR mutated advanced lung adenocarcinoma | PDF",1790032911,25]